FGS Global handles Alkermes plc as the biopharmaceutical seeks to thwart hedge fund Sarissa Capital’s bid to win board seats at the June 29 annual meeting.

Sarissa on June 20 picked up the support of independent proxy advisory ISS for one of its three nominees/candidates.

It concluded that shareholders’ interest would be best served by voting for Sarissa-nominated director Sarah Schlesinger.

ISS backed two of the three nominees put forth by Alkermes.

Glass Lewis & Co. on June 21 rose in opposition to Schlesinger’s nomination.

It believes her skills are redundant with those of multiple directors already on Alkermes’ board.

GL&C also noted that three of the four public companies at which Schlesinger served as a director “have materially underpeformed the industry index during her board tenure.”

The proxy advisor supports all seven of Alkermes’ director nominees.

FGS Global's Chris Kittredge and Zachary Tramonti represent Alkermes